The firm revised its revenue guidance for full-year 2026 to a range of $802 million to $806 million, and its net loss for the year to a range of $42 million to $34 million.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

An analyst acknowledged Abbott's diagnostics business faces some downside risks, but its medical technology business is buoyed by potential tailwinds.